With the continuous improvement of China’s economic development level，people’s demand for innovative pharmaceutical products is also higher. While pharmaceutical enterprises pay attention to their own product innovation and R&D，they also carry out licensing and introduction transactions of innovative drugs more and more frequently. In order to promote the rapid listing of innovative drugs，China has launched a green channel registration system for drugs. The Drug Administration Law revised in 2019 defines the drug listing license holder system. Combined with the patent connection system of traditional Chinese medicine in the Patent Law of 2020，it provides an institutional and legal guarantee for the subsequent smooth listing of authorized imported drugs.